{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:21:22Z","timestamp":1789507282227,"version":"build-2803163510"},"reference-count":84,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"LOEWE Centre for Translational Biodiversity Genomics","award":["LOEWE-TBG"],"award-info":[{"award-number":["LOEWE-TBG"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Multiple outbreaks of epidemic and pandemic viral diseases have occurred in the last 20 years, including those caused by Ebola virus, Zika virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence or re-emergence of such diseases has revealed the deficiency in our pipeline for the discovery and development of antiviral drugs. One promising solution is the extensive library of antimicrobial peptides (AMPs) produced by all eukaryotic organisms. AMPs are widely known for their activity against bacteria, but many possess additional antifungal, antiparasitic, insecticidal, anticancer, or antiviral activities. AMPs could therefore be suitable as leads for the development of new peptide-based antiviral drugs. Sixty therapeutic peptides had been approved by the end of 2018, with at least another 150 in preclinical or clinical development. Peptides undergoing clinical trials include analogs, mimetics, and natural AMPs. The advantages of AMPs include novel mechanisms of action that hinder the evolution of resistance, low molecular weight, low toxicity toward human cells but high specificity and efficacy, the latter enhanced by the optimization of AMP sequences. In this opinion article, we summarize the evidence supporting the efficacy of antiviral AMPs and discuss their potential to treat emerging viral diseases including COVID-19.<\/jats:p>","DOI":"10.3390\/v13050912","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T02:31:34Z","timestamp":1621218694000},"page":"912","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-8452","authenticated-orcid":false,"given":"Miray","family":"Tonk","sequence":"first","affiliation":[{"name":"Institute for Insect Biotechnology, Justus Liebig University of Giessen, Heinrich-Buff-Ring 26-32, 35392 Giessen, Germany"},{"name":"LOEWE Centre for Translational Biodiversity Genomics (LOEWE-TBG), Senckenberganlage 25, 60325 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4655-2380","authenticated-orcid":false,"given":"Daniel","family":"R\u016f\u017eek","sequence":"additional","affiliation":[{"name":"Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic"},{"name":"Biology Centre of the Czech Academy of Sciences, Institute of Parasitology, Branisovska 31, 37005 Ceske Budejovice, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8276-4968","authenticated-orcid":false,"given":"Andreas","family":"Vilcinskas","sequence":"additional","affiliation":[{"name":"Institute for Insect Biotechnology, Justus Liebig University of Giessen, Heinrich-Buff-Ring 26-32, 35392 Giessen, Germany"},{"name":"LOEWE Centre for Translational Biodiversity Genomics (LOEWE-TBG), Senckenberganlage 25, 60325 Frankfurt, Germany"},{"name":"Department of Bioresources, Fraunhofer Institute for Molecular Biology and Applied Ecology, Ohlebergsweg 12, 35392 Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jinf.2020.03.041","article-title":"Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in China: A Systematic Review and Meta-Analysis","volume":"80","author":"Fu","year":"2020","journal-title":"J. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Khan, S., Siddique, R., Shereen, M.A., Ali, A., Liu, J., Bai, Q., Bashir, N., and Xue, M. (2020). Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options. J. Clin. Microbiol., 58.","DOI":"10.1128\/JCM.00187-20"},{"key":"ref_4","unstructured":"WHO (2021, March 30). Coronavirus (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_5","unstructured":"(2021, March 30). COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available online: https:\/\/coronavirus.jhu.edu\/map.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/22221751.2020.1744483","article-title":"The Different Clinical Characteristics of Corona Virus Disease Cases between Children and Their Families in China\u2014The Character of Children with COVID-19","volume":"9","author":"Su","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","article-title":"Coronavirus Vaccine Development: From SARS and MERS to COVID-19","volume":"27","author":"Li","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106080","DOI":"10.1016\/j.ijantimicag.2020.106080","article-title":"COVID-19 Treatment: Close to a Cure? A Rapid Review of Pharmacotherapies for the Novel Coronavirus (SARS-CoV-2)","volume":"56","author":"Song","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Eastman, R.T., Roth, J.S., Brimacombe, K.R., Simeonov, A., Shen, M., Patnaik, S., and Hall, M.D. (2020). Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent. Sci.","DOI":"10.20944\/preprints202004.0299.v1"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jmv.25798","article-title":"Novel Coronavirus Treatment with Ribavirin: Groundwork for an Evaluation Concerning COVID-19","volume":"92","author":"Khalili","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s00134-020-06223-y","article-title":"The Ten Reasons Why Corticosteroid Therapy Reduces Mortality in Severe COVID-19","volume":"46","author":"Arabi","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jinf.2020.03.062","article-title":"The Effect of Corticosteroid Treatment on Patients with Coronavirus Infection: A Systematic Review and Meta-Analysis","volume":"81","author":"Yang","year":"2020","journal-title":"J. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1198","DOI":"10.1002\/cti2.1198","article-title":"Intravenous Immunoglobulin Immunotherapy for Coronavirus Disease-19 (COVID-19)","volume":"9","author":"Galeotti","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e008688","DOI":"10.1161\/CIRCEP.120.008688","article-title":"Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications","volume":"13","author":"Oren","year":"2020","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"16826","DOI":"10.1038\/s41598-020-74001-3","article-title":"Preemptive Interleukin-6 Blockade in Patients with COVID-19","volume":"10","author":"Padilla","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"110698","DOI":"10.1016\/j.biopha.2020.110698","article-title":"The Role of Interleukin 6 Inhibitors in Therapy of Severe COVID-19","volume":"131","author":"Nasonov","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijid.2020.07.023","article-title":"Early Administration of Interleukin-6 Inhibitors for Patients with Severe COVID-19 Disease Is Associated with Decreased Intubation, Reduced Mortality, and Increased Discharge","volume":"99","author":"Sinha","year":"2020","journal-title":"Int. J. Infect. Dis. IJID"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bj.2020.11.011","article-title":"Neutralizing Monoclonal Antibodies for COVID-19 Treatment and Prevention","volume":"44","author":"Jaworski","year":"2021","journal-title":"Biomed. J."},{"key":"ref_20","unstructured":"Wagner, E., and Hewlett, M. (1999). WW|Retrovirus. Basic Virology, Blackwell. [3rd ed.]."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.tips.2013.11.006","article-title":"Current Progress in Antiviral Strategies","volume":"35","author":"Lou","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bakovic, A., Risner, K., Bhalla, N., Alem, F., Chang, T.L., Weston, W., Harness, J.A., and Narayanan, A. (2020). Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2. bioRxiv.","DOI":"10.1101\/2020.10.29.352450"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Elnagdy, S., and AlKhazindar, M. (2020). The Potential of Antimicrobial Peptides as an Antiviral Therapy against COVID-19. ACS Pharmacol. Transl. Sci.","DOI":"10.1021\/acsptsci.0c00059"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MOH.0000000000000005","article-title":"Defensins in Innate Immunity","volume":"21","author":"Zhao","year":"2014","journal-title":"Curr. Opin. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.0105-2896.2004.0124.x","article-title":"Anti-Microbial Peptides: From Invertebrates to Vertebrates","volume":"198","author":"Bulet","year":"2004","journal-title":"Immunol. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/CMR.00056-05","article-title":"Peptide Antimicrobial Agents","volume":"19","author":"Jenssen","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_27","first-page":"3919","article-title":"The Antimicrobial Peptides and Their Potential Clinical Applications","volume":"11","author":"Lei","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.abf4896","article-title":"Intranasal Fusion Inhibitory Lipopeptide Prevents Direct-Contact SARS-CoV-2 Transmission in Ferrets","volume":"371","author":"Schmitz","year":"2021","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/psc.2489","article-title":"Peptide Inhibitors against Herpes Simplex Virus Infections","volume":"19","author":"Galdiero","year":"2013","journal-title":"J. Pept. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/1479-5876-11-305","article-title":"VIRsiRNApred: A Web Server for Predicting Inhibition Efficacy of SiRNAs Targeting Human Viruses","volume":"11","author":"Qureshi","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.micinf.2015.10.009","article-title":"Identification of Innate Immune Antiretroviral Factors during in Vivo and in Vitro Exposure to HIV-1","volume":"18","author":"Zapata","year":"2016","journal-title":"Microbes Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1016\/j.jmb.2013.09.038","article-title":"Antiviral Mechanisms of Human Defensins","volume":"425","author":"Wilson","year":"2013","journal-title":"J. Mol. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8658","DOI":"10.4049\/jimmunol.177.12.8658","article-title":"Human Alpha- and Beta-Defensins Block Multiple Steps in Herpes Simplex Virus Infection","volume":"177","author":"Hazrati","year":"2006","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"28821","DOI":"10.1074\/jbc.M112.375949","article-title":"Multifaceted Mechanisms of HIV-1 Entry Inhibition by Human \u03b1-Defensin","volume":"287","author":"Demirkhanyan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/cb1001558","article-title":"Describing the Mechanism of Antimicrobial Peptide Action with the Interfacial Activity Model","volume":"5","author":"Wimley","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/ni1248","article-title":"Carbohydrate-Binding Molecules Inhibit Viral Fusion and Entry by Crosslinking Membrane Glycoproteins","volume":"6","author":"Leikina","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bcp.2012.12.011","article-title":"Antivirals: Past, Present and Future","volume":"85","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccm.2016.11.008","article-title":"Antiviral Treatments","volume":"38","author":"Ison","year":"2017","journal-title":"Clin. Chest Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fmicb.2013.00321","article-title":"Current Scenario of Peptide-Based Drugs: The Key Roles of Cationic Antitumor and Antiviral Peptides","volume":"4","author":"Mulder","year":"2013","journal-title":"Front. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1128\/jvi.60.3.1068-1074.1986","article-title":"Direct Inactivation of Viruses by Human Granulocyte Defensins","volume":"60","author":"Daher","year":"1986","journal-title":"J. Virol."},{"key":"ref_41","first-page":"479","article-title":"Cationic Host Defence Peptides: Potential as Antiviral Therapeutics","volume":"27","author":"Currie","year":"2013","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3851\/IMP2077","article-title":"Antiviral Activity of Recombinant Mouse \u03b2-Defensin 3 against Influenza A Virus in Vitro and in Vivo","volume":"22","author":"Jiang","year":"2012","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4062\/biomolther.2017.172","article-title":"Towards the Application of Human Defensins as Antivirals","volume":"26","author":"Park","year":"2018","journal-title":"Biomol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1038\/s41467-020-17986-9","article-title":"A Broad-Spectrum Virus- and Host-Targeting Peptide against Respiratory Viruses Including Influenza Virus and SARS-CoV-2","volume":"11","author":"Zhao","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41467-018-04792-7","article-title":"Dual-Functional Peptide with Defective Interfering Genes Effectively Protects Mice against Avian and Seasonal Influenza","volume":"9","author":"Zhao","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15672","DOI":"10.1038\/ncomms15672","article-title":"A Peptide-Based Viral Inactivator Inhibits Zika Virus Infection in Pregnant Mice and Fetuses","volume":"8","author":"Yu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/ncomms4067","article-title":"Structure-Based Discovery of Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor","volume":"5","author":"Lu","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.peptides.2011.05.015","article-title":"Virucidal Activity of a Scorpion Venom Peptide Variant Mucroporin-M1 against Measles, SARS-CoV and Influenza H5N1 Viruses","volume":"32","author":"Li","year":"2011","journal-title":"Peptides"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1074\/jbc.M411141200","article-title":"Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in Gp41 and Gp120","volume":"280","author":"Liu","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.biotechadv.2018.01.004","article-title":"Designing Improved Active Peptides for Therapeutic Approaches against Infectious Diseases","volume":"36","author":"Gomes","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nprot.2015.053","article-title":"The Phyre2 Web Portal for Protein Modeling, Prediction and Analysis","volume":"10","author":"Kelley","year":"2015","journal-title":"Nat. Protoc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"eaav4580","DOI":"10.1126\/sciadv.aav4580","article-title":"A Pan-Coronavirus Fusion Inhibitor Targeting the HR1 Domain of Human Coronavirus Spike","volume":"5","author":"Xia","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion Mechanism of 2019-NCoV and Fusion Inhibitors Targeting HR1 Domain in Spike Protein","volume":"17","author":"Xia","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"22008","DOI":"10.1038\/srep22008","article-title":"A Novel Peptide with Potent and Broad-Spectrum Antiviral Activities against Multiple Respiratory Viruses","volume":"6","author":"Zhao","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/j.gastro.2020.05.015","article-title":"Human Intestinal Defensin 5 Inhibits SARS-CoV-2 Invasion by Cloaking ACE2","volume":"159","author":"Wang","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mahendran, A.S.K., Lim, Y.S., Fang, C.-M., Loh, H.-S., and Le, C.F. (2020). The Potential of Antiviral Peptides as COVID-19 Therapeutics. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.575444"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9920","DOI":"10.1021\/bi700720e","article-title":"Retrocyclin-2: Structural Analysis of a Potent Anti-HIV Theta-Defensin","volume":"46","author":"Daly","year":"2007","journal-title":"Biochemistry"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.peptides.2013.07.014","article-title":"A Mastoparan-Derived Peptide Has Broad-Spectrum Antiviral Activity against Enveloped Viruses","volume":"48","author":"Sample","year":"2013","journal-title":"Peptides"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.dci.2016.11.013","article-title":"Characterization and Antiviral Activity of a Newly Identified Defensin-like Peptide, HEdefensin, in the Hard Tick Haemaphysalis Longicornis","volume":"68","author":"Talactac","year":"2017","journal-title":"Dev. Comp. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13071-016-1344-5","article-title":"Virucidal Activity of Haemaphysalis longicornis Longicin P4 Peptide against Tick-Borne Encephalitis Virus Surrogate Langat Virus","volume":"9","author":"Talactac","year":"2016","journal-title":"Parasit. Vectors"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1074\/jbc.RA118.005015","article-title":"A Scorpion Venom Peptide Ev37 Restricts Viral Late Entry by Alkalizing Acidic Organelles","volume":"294","author":"Li","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.cell.2015.09.056","article-title":"Engineering a Therapeutic Lectin by Uncoupling Mitogenicity from Antiviral Activity","volume":"163","author":"Swanson","year":"2015","journal-title":"Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"17598","DOI":"10.1074\/jbc.M111.338970","article-title":"Novel Cyclotides and Uncyclotides with Highly Shortened Precursors from Chassalia chartacea and Effects of Methionine Oxidation on Bioactivities","volume":"287","author":"Nguyen","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.peptides.2004.08.003","article-title":"Coccinin, an Antifungal Peptide with Antiproliferative and HIV-1 Reverse Transcriptase Inhibitory Activities from Large Scarlet Runner Beans","volume":"25","author":"Ngai","year":"2004","journal-title":"Peptides"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1021\/jo990952r","article-title":"Cycloviolins A\u2013D, Anti-HIV Macrocyclic Peptides from Leonia cymosa","volume":"65","author":"Hallock","year":"2000","journal-title":"J. Org. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/(SICI)1099-1387(199804)4:2<111::AID-PSC134>3.0.CO;2-8","article-title":"The Maculatin Peptides from the Skin Glands of the Tree Frog Litoria genimaculata: A Comparison of the Structures and Antibacterial Activities of Maculatin 1.1 and Caerin 1.1","volume":"4","author":"Rozek","year":"1998","journal-title":"J. Pept. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Stone, D.J.M., Waugh, R.J., Bowie, J.H., Wallace, J.C., and Tyler, M.J. (1992). Peptides from Australian Frogs. Structures of the Caerins and Caeridin 1 from Litoria splendida. J. Chem. Soc. Perkin Trans., 3173\u20133178.","DOI":"10.1039\/p19920003173"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2017.03.018","article-title":"An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses","volume":"46","author":"Holthausen","year":"2017","journal-title":"Immunity"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000238875","article-title":"Direct Virus Inactivation of Tachyplesin I and Its Isopeptides from Horseshoe Crab Hemocytes","volume":"37","author":"Murakami","year":"1991","journal-title":"Chemotherapy"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1128\/AAC.41.7.1521","article-title":"Discovery of Cyanovirin-N, a Novel Human Immunodeficiency Virus-Inactivating Protein That Binds Viral Surface Envelope Glycoprotein Gp120: Potential Applications to Microbicide Development","volume":"41","author":"Boyd","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1038\/s41598-017-04777-4","article-title":"Inhibition of Highly Pathogenic Avian Influenza (HPAI) Virus by a Peptide Derived from VFLIP through Its Direct Destabilization of Viruses","volume":"7","author":"Moon","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IDR.S105473","article-title":"Drug Resistance in Influenza A Virus: The Epidemiology and Management","volume":"10","author":"Hussain","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/bmj.317.7159.660","article-title":"Antiviral Drug Resistance","volume":"317","author":"Pillay","year":"1998","journal-title":"BMJ"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Chang, K.Y., and Yang, J.-R. (2013). Analysis and Prediction of Highly Effective Antiviral Peptides Based on Random Forests. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070166"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1128\/AAC.48.4.1300-1306.2004","article-title":"Relationship between Antiviral Activity and Host Toxicity: Comparison of the Incorporation Efficiencies of 2\u2032,3\u2032-Dideoxy-5-Fluoro-3\u2032-Thiacytidine-Triphosphate Analogs by Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Human Mitochondrial DNA Polymerase","volume":"48","author":"Feng","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrd1151","article-title":"Toxicity of Antiretroviral Therapy and Implications for Drug Development","volume":"2","author":"Carr","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000494354","article-title":"Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins","volume":"61","author":"Sala","year":"2018","journal-title":"Intervirology"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Agarwal, G., and Gabrani, R. (2020). Antiviral Peptides: Identification and Validation. Int. J. Pept. Res. Ther., 1\u201320.","DOI":"10.1007\/s10989-020-10072-0"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Yuan, L., Zhang, S., Peng, J., Li, Y., and Yang, Q. (2019). Synthetic Surfactin Analogues Have Improved Anti-PEDV Properties. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215227"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s00018-019-03138-w","article-title":"Antiviral Peptides as Promising Therapeutic Drugs","volume":"76","author":"Campos","year":"2019","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","article-title":"Strategic Approaches to Optimizing Peptide ADME Properties","volume":"17","author":"Di","year":"2015","journal-title":"AAPS J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semcdb.2018.03.001","article-title":"Mining the Tree of Life: Host Defense Peptides as Antiviral Therapeutics","volume":"88","author":"Shartouny","year":"2019","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature10702","article-title":"Rethinking Amide Bond Synthesis","volume":"480","author":"Pattabiraman","year":"2011","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.coph.2008.06.002","article-title":"Discovering and Improving Novel Peptide Therapeutics","volume":"8","author":"McGregor","year":"2008","journal-title":"Curr. Opin. Pharmacol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/5\/912\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:01:01Z","timestamp":1760162461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/5\/912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":84,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["v13050912"],"URL":"https:\/\/doi.org\/10.3390\/v13050912","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]}}}